SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
暂无分享,去创建一个
Edwin DeJesus | Jane Yeo | A. Gładysz | R. Wood | D. Schürmann | P. Ive | Robin Wood | J. Gathe | E. Dejesus | N. Bellos | Dirk Schürmann | Nicholaos C Bellos | Joseph C Gathe | Prudence Ive | Andrzej Gladysz | Cindy Garris | J. Yeo | C. Garris | Nicholaos C. Bellos
[1] B. Sadler,et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers , 2001, AIDS.
[2] Victor De Gruttola,et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.
[3] R D Moore,et al. Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. , 2000, JAMA.
[4] J. Schapiro,et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study , 2000, AIDS.
[5] G. Gray,et al. The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy–Naive HIV-1-Infected Patients , 2004, Journal of acquired immune deficiency syndromes.
[6] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[7] O. Naderer,et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.
[8] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[9] 俊郎 黒木,et al. Centers for Disease Control and Prevention (CDC) ホームページの活用法 , 2002 .
[10] L. Bekker,et al. Antiretroviral therapy in a community clinic--early lessons from a pilot project. , 2003, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[11] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[12] C. Hendrix,et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers , 2004, AIDS.
[13] H. Stellbrink,et al. Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients , 2004, Antimicrobial Agents and Chemotherapy.
[14] Michael S Saag,et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. , 2002, JAMA.
[15] B. Sadler,et al. Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir , 2002, Antimicrobial Agents and Chemotherapy.
[16] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[17] R Weber,et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.
[18] K. Squires,et al. Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects , 2003, Journal of acquired immune deficiency syndromes.
[19] D. Roter,et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. , 2002, Patient education and counseling.
[20] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.